HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer.


Journal

Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230

Informations de publication

Date de publication:
04 2023
Historique:
received: 19 05 2022
accepted: 09 12 2022
revised: 29 11 2022
medline: 18 4 2023
pubmed: 28 12 2022
entrez: 27 12 2022
Statut: ppublish

Résumé

Integration of high-dimensional tumor gene expression data with clinicopathological data can increase our understanding of disease diversity, enable retrospective patient stratification, and identify new potential biomarkers and therapeutic targets. Using a systems biology approach, we provide a holistic overview of gene co-expression networks in head and neck squamous cell carcinomas (HNSCC). Weighted gene co-expression network analysis of HNSCC RNA sequencing data from 519 patients from The Cancer Genome Atlas (TCGA) was used to determine correlates of 5-year survival, using regression tree-based optimal threshold calculations. Survival-associated gene sets were transformed to gene set scores that were assessed for correlation with clinicopathological data. We identified 8 gene co-expression modules for HNSCC tumors, each of which contained co-expressed genes associated significantly with 5-year survival. Survival-associated co-expression gene signatures correlated dominantly with tumor HPV and p16 status. Network analysis identified that survival was associated with signaling networks of infection, immunity, epithelial-mesenchymal transition (EMT), hypoxia, glycolysis, focal adhesion, extracellular matrix, MYC signaling, autophagy and transcriptional regulation. EMT-associated gene signatures were expressed dominantly in fibroblasts, and cancer-associated fibroblasts were inversely correlated with immune activity. Interestingly, a high Immune Suppression Score based on expression of 21 genes associated with immune inhibition and including immune checkpoints, cytokines and regulatory T cell factors, was also associated with increased survival probability, and was significantly higher in HPV+ HNSCC. Networks associated with HNSCC survival were further associated with survival in cervical cancer, melanoma and lung cancer. This study defines 5129 genes associated with HNSCC survival, organized into co-expressed networks, their correlation with clinicopathological data, and with gene expression data from other malignant diseases, and provides a source for the discovery of biomarkers and novel therapies for HNSCC.

Identifiants

pubmed: 36575316
doi: 10.1038/s41417-022-00577-9
pii: 10.1038/s41417-022-00577-9
pmc: PMC10104777
doi:

Substances chimiques

Proto-Oncogene Proteins c-myc 0
Biomarkers 0
Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

629-640

Informations de copyright

© 2022. The Author(s).

Références

Nat Commun. 2020 Jan 24;11(1):515
pubmed: 31980601
Nat Methods. 2017 Nov;14(11):1083-1086
pubmed: 28991892
J Stat Softw. 2012 Mar;46(11):
pubmed: 23050260
J Gen Virol. 2021 Mar;102(3):
pubmed: 33427604
Mol Cancer. 2021 Apr 29;20(1):73
pubmed: 33926453
Sci Rep. 2022 Nov 4;12(1):18710
pubmed: 36333579
Laryngoscope. 2019 Nov;129(11):2506-2513
pubmed: 30637762
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690
Cell Death Discov. 2017 Nov 13;3:17071
pubmed: 29152378
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Cells. 2020 Apr 04;9(4):
pubmed: 32260326
Oral Dis. 2015 Apr;21(3):283-91
pubmed: 24797102
J Exp Med. 2007 Jun 11;204(6):1257-65
pubmed: 17502665
BMC Bioinformatics. 2018 Nov 6;19(1):404
pubmed: 30400809
Radiol Clin North Am. 2021 Sep;59(5):773-788
pubmed: 34392918
Mol Cancer. 2021 Jan 4;20(1):3
pubmed: 33397405
Nature. 2005 Jul 7;436(7047):123-7
pubmed: 16001073
Oral Oncol. 2016 Jul;58:8-13
pubmed: 27311396
Clin Cancer Res. 2008 Jul 15;14(14):4584-92
pubmed: 18628473
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Exp Mol Pathol. 2011 Apr;90(2):215-25
pubmed: 21236253
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Oncogene. 2019 Jun;38(25):4887-4901
pubmed: 30816343
Front Mol Biosci. 2021 Mar 23;8:622643
pubmed: 33834038
Laryngorhinootologie. 2018 Mar;97(S 01):S48-S113
pubmed: 29905354
J Oral Pathol Med. 2009 Nov;38(10):759-63
pubmed: 19453846
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Int J Mol Sci. 2020 Oct 30;21(21):
pubmed: 33143224
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Br J Radiol. 2019 Jan;92(1093):20180047
pubmed: 29493265
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
Front Oncol. 2020 Nov 27;10:565306
pubmed: 33330034
Oncoimmunology. 2020 Apr 9;9(1):1744946
pubmed: 33457090
iScience. 2021 Mar 26;24(4):102368
pubmed: 33889830
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Cancer Cell Int. 2020 Oct 12;20:500
pubmed: 33061852
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Ahmed M Mehdi (AM)

Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
Queensland Cyber Infrastructure Foundation Ltd, Facility for Advanced Bioinformatics, Brisbane, QLD, 4072, Australia.

Chenhao Zhou (C)

Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, 4102, Australia.

Gavin Turrell (G)

Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, 4102, Australia.

Euan Walpole (E)

Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.

Sandro Porceddu (S)

Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
Peter MacCallum Cancer Centre, Radiation Oncology, Melbourne, VIC, 3000, Australia.

Ian H Frazer (IH)

Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, 4102, Australia.

Janin Chandra (J)

Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, 4102, Australia. j.chandra@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH